<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:8pt Arial, sans-serif; }
 .font2 { font:9pt Arial, sans-serif; }
 .font3 { font:16pt Arial, sans-serif; }
 .font4 { font:13pt Times New Roman, serif; }
 .font5 { font:19pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font5">J.P. Morgan</span></p>
<p><span class="font2" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.2hao@jpmorgan.com"><span class="font0" style="font-weight:bold;">isabella.2hao@jpmorgan.com</span></a></p>
<div>
<p><span class="font1">16,000</span></p>
</div><br clear="all">
<div>
</div><br clear="all">
<div>
<p><span class="font1">4,000 ■</span></p>
</div><br clear="all">
<div>
<p><span class="font1">2,000 ■</span></p>
</div><br clear="all">
<div>
<p><span class="font1">0</span></p>
</div><br clear="all">
<div>
<p><span class="font1">4.3%</span></p>
<p><span class="font1">4.2%</span></p>
<p><span class="font1">4.1%</span></p>
<p><span class="font1">4.0%</span></p>
<p><span class="font1">3.9%</span></p>
<p><span class="font1">3.8%</span></p>
<p><span class="font1">3.7%</span></p>
<p><span class="font1" style="font-weight:bold;">3.6%</span></p>
<p><span class="font1">3.5%</span></p>
<p><span class="font1" style="font-weight:bold;">3.4%</span></p>
<p><span class="font1">3.3%</span></p>
<p><span class="font1">3.2%</span></p>
</div><br clear="all">
<div>
<p><span class="font1">2012</span></p>
</div><br clear="all">
<div>
<p><span class="font1" style="font-weight:bold;">2013</span></p>
</div><br clear="all">
<div>
<p><span class="font1" style="font-weight:bold;">2014</span></p>
</div><br clear="all">
<div>
<p><span class="font1">2015</span></p>
</div><br clear="all">
<div>
<p><span class="font1" style="font-weight:bold;">2016E</span></p>
</div><br clear="all">
<div>
<p><span class="font1" style="font-weight:bold;">201</span><span class="font1">7E</span></p>
</div><br clear="all">
<div>
<p><span class="font1">2018E</span></p>
</div><br clear="all">
<p><span class="font1">Source: J.P. Morgan estimates, Company data</span></p>
<div>
</div><br clear="all"><a name="caption1"></a>
<h6><a name="bookmark0"></a><span class="font3" style="font-weight:bold;"><a name="bookmark1"></a>Balance sheet and cash flow</span></h6>
<p><span class="font4">Sinopharm generated operating cash flow of Rmbl3,560mn in 2015, which is a significant increase from Rmb 5,560mn in 2014. It also has a strong balance sheet with total assets of Rmbl38,267mn, up from Rmbl28,655mn in 2014. The company's cash and equivalents increased to Rmbl9,919mn in 2015, an increase of 30.7% from 2014. In 1H16, total assets amounted to Rmbl52,539mn, an increase of 10.3% from 2015.</span></p>
<p><span class="font4">More importantly, gearing ratio (ND/E) were 39% as of 1H16, we expect continuous decreasing interest expense and growing cash flow going forward.</span></p>
<p><span class="font0" style="font-weight:bold;">17</span></p>
</body>
</html>